Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Galectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly



Galectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its
Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and
Portal Hypertension

Findings Suggest Role for GR-MD-02 and GM-CT-01 in Treatment of Liver Fibrosis
and Cirrhosis in Humans

NORCROSS, Ga., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics
(Nasdaq:GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that new preclinical
data show its galectin inhibitors, GR-MD-02 and GM-CT-01, have significant
therapeutic effects on fibrosis regression and cirrhosis reversal. Results
were published in an article titled "Regression of Fibrosis and Reversal of
Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver
Disease" in PLOS ONE, an international, open-access journal with rigorous peer
review.

In the preclinical study, fibrosis was induced in rats by injecting
thioacetamide (TAA) into the abdominal cavity. Rats were then treated with
GR-MD-02 (galactoarabino-rhamnogalaturonan) or GM-CT-01 (galactomannan). In
the initial part of the study, rats that completed eight weeks of
thioacetamide injections were given four weeks of treatment with GR-MD-02;
results showed an almost 50 percent reduction in collagen content, a marker of
chronic fibrosis. Rats were then exposed to additional thioacetamide
injections and developed extensive fibrosis (cirrhosis); treatment with four
once weekly doses of GR-MD-02 or GM-CT-01 while continuing treatment with the
toxin TAA led to marked reduction in fibrosis and reversal of cirrhosis.
Overall, the study demonstrated that GR-MD-02 or GM-CT-01 led to significantly
reduced fibrosis, reversal of cirrhosis and a significant reduction in portal
hypertension.

"These preclinical data suggest a potential role for GR-MD-02 and GM-CT-01 in
the treatment of liver fibrosis and cirrhosis in humans," said Peter G.
Traber, MD, President, Chief Executive Officer and Chief Medical Officer,
Galectin Therapeutics Inc. "There are currently no approved therapies for
fibrosis. Encouraging data like these published in PLOS ONE increase the body
of scientific knowledge of galectin inhibitors and add momentum to Galectin
Therapeutics' development program. We recently announced that GR-MD-02
received Fast Track designation from the FDA for fatty liver disease with
advanced fibrosis."

The preclinical study was conducted predominantly at the Icahn School of
Medicine at Mount Sinai in New York City. The senior author, Dr. Scott
Friedman of Mount Sinai, is an international expert in the pathogenesis and
treatment of liver fibrosis. The PLOS ONE article can be found online at
http://dx.plos.org/10.1371/journal.pone.0075361

GM-CT-01 and GR-MD-02 are proprietary molecules, which are generated from
naturally occurring carbohydrate polymers using proprietary processes, and
possess the property of binding to and inhibiting galectin proteins,
predominantly galectin-3. In July, the Company successfully dosed the first
patient in a Phase 1 clinical trial of GR-MD-02 and enrollment is ongoing.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development expertise as
well as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear development
pathway to clinical enhancement and commercialization for our lead compounds
in liver fibrosis and cancer. Additional information is available at
www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. These statements
include those regarding the potential role for GR-MD-02 and GM-CT-01 in the
treatment of liver fibrosis and cirrhosis in humans. Factors that could cause
our actual performance to differ materially from those discussed in the
forward-looking statements include, among others, that our plans, expectations
and goals regarding any potential therapeutic uses and benefits of our drugs
and any future pre-clinical or clinical studies are subject to factors beyond
our control. Future clinical studies may not begin or produce positive results
in a timely fashion, if at all, and could prove time consuming and costly.
Plans regarding development, approval and marketing of any of our drugs are
subject to change at any time based on the changing needs of our company as
determined by management and regulatory agencies. Regardless of the results of
current or future studies, we may be unsuccessful in developing partnerships
with other companies or obtaining capital that would allow us to further
develop and/or fund any studies or trials. To date, we have incurred operating
losses since our inception, and our ability to successfully develop and market
drugs may be impacted by our ability to manage costs and finance our
continuing operations. For a discussion of additional factors impacting our
business, see our Annual Report on Form 10-K for the year ended December 31,
2012, and our subsequent filings with the SEC. You should not place undue
reliance on forward-looking statements. Although subsequent events may cause
our views to change, we disclaim any obligation to update forward-looking
statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO, & CMO
         ir@galectintherapeutics.com

Galectin Therapeutics, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement